Boardroom Alpha
Meeting calendar
PBI · Annual meeting · Tuesday, May 12, 2026

Pitney Bowes Inc

5 nominees · 3 ballot items.

Election of five directors; ratification of PricewaterhouseCoopers LLP as independent auditors for 2026; and a non-binding advisory (say-on-pay) vote to approve the compensation of the named executive officers as disclosed in the proxy statement.

Market cap
$2.5B
1Y TSR
+55.6%
Board grade
B-
Record date
Mar 16, 2026
Filing
DEF 14A
Meeting concluded · May 12, 2026

Follow how the vote landed and what changed on Pitney Bowes Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect five directors to the Board to serve until the 2027 Annual Meeting.

  2. 2

    Ratification of the Appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accountants for 2026

    ManagementBoard: FOR

    Ratify the Audit Committee’s selection of PricewaterhouseCoopers LLP (PwC) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  3. 3

    Non-Binding Advisory Vote to Approve Executive Compensation

    ManagementBoard: FOR

    Advisory (non-binding) 'say-on-pay' vote to approve the compensation of the named executive officers as disclosed in the Compensation Discussion and Analysis and related tables.

    More detail

    This management-sponsored, non-binding advisory proposal asks shareholders to approve the Company’s named executive officer (NEO) compensation as disclosed in the Compensation Discussion and Analysis and related tables. Management frames the vote as a routine say-on-pay advisory mechanism required by SEC rules, and the Board has recommended a FOR vote because it believes the program ties pay to measurable performance and supports retention of key leaders during the Company’s transformation. Key context includes the CEO transition in 2025, substantial organizational and leadership changes, and incentive design changes such as premium-priced stock options for the new CEO and a mix of performance stock units (PSUs), restricted stock units (RSUs) and historically cash-settled CIUs/SCIUs for other NEOs. The compensation program relies on enterprise financial metrics (Adjusted EBIT and Adjusted Revenue for annual incentives; Adjusted EPS and Adjusted FCF for multi-year PSUs) and a relative TSR modifier for long-term awards, intended to align pay with both absolute financial performance and relative shareholder returns. Management also emphasizes a high proportion of pay “at-risk,” stock ownership guidelines, clawback provisions, no hedging/pledging, independent compensation consulting, and ongoing stockholder engagement as governance safeguards. The Board notes that the vote is advisory and will be considered in future compensation decisions; it also states the next advisory vote is expected at the 2027 Annual Meeting. From a governance perspective, the controversy centers on whether the chosen metrics, the concentration of premium-priced options for the CEO, and the historically changing LTI mix (including prior use of cash-settled CIUs to manage dilution) adequately balance shareholder alignment, dilution control, and executive retention. Given management’s recent operational progress, share repurchases, and the Board’s outreach to investors, the recommendation for approval is positioned as support for the current pay-for-performance framework while remaining responsive to future shareholder feedback.

Director elections

Nominees on the ballot5

Independent
Tenure on this board
1.1 yrs
Also a director at
Syntec Optics Holdings Inc (OPTX)SLGDD
Independent
Tenure on this board
0.8 yrs
Also a director at
Outdoor Holding Co (POWW)Pharmacyte Biotech Inc (PMCB)
Not independent
Tenure on this board
3.2 yrs
Ownership

Top institutional holders10

Latest 13F quarter
1BlackRock, Inc.8.3%11,222,733$124M
2VANGUARD PORTFOLIO MANAGEMENT LLC6.2%8,398,571$93M
3Hestia Capital Management, LLC6.0%8,155,805$90M
4STATE STREET CORP4.7%6,417,472$71M
5LSV ASSET MANAGEMENT4.7%6,333,880$70M
6VANGUARD CAPITAL MANAGEMENT LLC4.5%6,059,626$67M
7Permit Capital, LLCActivist2.6%3,500,000$39M
8GEODE CAPITAL MANAGEMENT, LLC2.4%3,219,531$36M
9CAPITAL MANAGEMENT CORP /VA2.0%2,689,543$30M
10GOLDMAN SACHS GROUP INC1.9%2,570,817$28M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Pitney Bowes Inc 2026 annual meeting?
Pitney Bowes Inc (PBI) holds its 2026 annual shareholder meeting on Tuesday, May 12, 2026.
What is the record date for the Pitney Bowes Inc 2026 meeting?
The record date for the Pitney Bowes Inc 2026 meeting is Monday, March 16, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Pitney Bowes Inc's 2026 meeting?
The board is presenting 5 director nominees at the Pitney Bowes Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Pitney Bowes Inc 2026 meeting?
Shareholders will vote on 3 proposals at the Pitney Bowes Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer